

Figure S3. DNA dose optimization for transient transfection of secreted recombinant antibodies. In HEK cells, PEI was used at a 2:1 polymer:DNA w/w ratio, whereas in CHO cells, PEI was used at a 3:1 polymer:DNA w/w ratio. 4-4-6 was used at a 60:1 polymer:DNA w/w ratio in both cell lines. (A) Reducing SDS-PAGE analysis showing expression of the 10H2 monoclonal antibody following transient transfection of HEK cells with the indicated doses of DNA encapsulated in PEI (+) or 4-4-6 nanoparticles. (B) Quantification of 10H2 expression from (A), presented as fold improvement over PEI. (C) Reducing SDS-PAGE analysis showing expression of the BS2 bispecific antibody following transient transfection of HEK cells with the indicated doses of DNA encapsulated in PEI (+) or 4-4-6 nanoparticles. (D) Quantification of BS2 expression from (C), presented as fold improvement over PEI. (E) Reducing SDS-PAGE analysis showing expression of the 602 monoclonal antibody following transient transfection of CHO cells with the indicated doses of DNA encapsulated in PEI (+) or 4-4-6 nanoparticles. (F) Quantification of 602 expression from (E), presented as fold improvement over PEI. (G) Comparative yield (pre-FPLC) from transient transfection of CHO cells with the 602 monoclonal antibody utilizing 4-4-6 or PEI DNA-containing nanoparticles at 50 mL scale (4 µg/mL DNA dose). HC, heavy chain; LC, light chain.